WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-06-02·Latest →

Salesforce (CRM) Stock Analysis

UW

CRM Equity Research — UNDERWEIGHT — June 2026

← AVGOCSCO →

Rating date

Jun 2, 2026

69 days ago

Desk view

UW

5D move

-9.11%

Correct (early)

Peer rank

95p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · CRM

Here is the analysis for CRM (Salesforce) as of June 2, 2026.

Desk rating

UW

Tactical UW · 12M HOLD

Horizon

Tactical UNDERWEIGHT · 12M HOLD

Confidence

Medium

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

UNDERWEIGHT

Catalysts

  • CRM's narrative is currently anchored to AI more than core software fundamentals. The Anthropic investment ($50M → ~$5B) is the dominant positive story.
  • Earnings beat is real, but not fully trusted by the Street. The split between "beat estimates" and "one analyst still sees pain" suggests unresolved concerns about margin trajectory or growth durability.
  • TD Cowen's $250 Buy rating provides a bull-case anchor and suggests institutional conviction that CRM can sustain its recovery.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

CRM Research Note

Full desk note for Jun 2, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

30 min read

WebserviceX · Agentic Research Desk

CRM Equity Research Note

Published Jun 2, 2026 · Desk view UNDERWEIGHT · Generated 2026-06-03T04:53:43Z · Maintained by Walter Vijayakumar · Methodology · Track record

CRM Stock Rating Summary

CRM bias

UNDERWEIGHT

Horizon

Tactical UNDERWEIGHT · 12M HOLD

CRM key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

CRM catalyst watch

CRM's narrative is currently anchored to AI more than core software fundamentals. The Anthropic investment ($50M → ~$5B) is the dominant positive story.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Medium

How the call aged · 5D

-9.11%Correct (early)Peer 95p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-06-09T07:21:33.695681+00:00.

5D move

-9.11%

2026-06-02 → 2026-06-08

Outcome

Correct (early)

5D trend

+12.15%

Vol (20D ann.)

+58.02%

vs SPY: +10.95%

Close 200.84 → — (USD, vendor closes)

Batch scorecard · 2026-06-02 · CRM

Publish QC

passed
Expand

Pipeline fingerprint 781c0b04aa680fac

No QC issues recorded.